Product Description

🔹 Product Overview
Nintib 150 mg Soft Gelatin Capsules contain Nintedanib 150 mg, an oral tyrosine kinase inhibitor used primarily for the treatment of idiopathic pulmonary fibrosis (IPF) and, in appropriate treatment regimens, certain types of non-small cell lung cancer (NSCLC).

Nintedanib helps slow disease progression by inhibiting signaling pathways involved in abnormal blood-vessel formation and fibrotic processes. Nintib 150 mg is a prescription medicine and should be used under specialist medical supervision.

🔹 Composition
Active Ingredient: Nintedanib 150 mg
Salt Form: Nintedanib Ethanesulfonate, equivalent to Nintedanib 150 mg
Brand: Nintib 150 mg
Dosage Form: Soft gelatin capsule
Therapeutic Class: Tyrosine kinase inhibitor / Antineoplastic and antifibrotic medicine


🔹 Uses And Indications
Nintib 150 mg may be prescribed for:
Idiopathic pulmonary fibrosis (IPF)
Chronic fibrosing interstitial lung disease with a progressive phenotype, where approved
Systemic sclerosis-associated interstitial lung disease (SSc-ILD), where approved
Certain non-small cell lung cancers (NSCLC) in combination with docetaxel, according to the applicable treatment indication and local prescribing information.

🔹 How It Works
Nintedanib inhibits several receptor tyrosine kinases, including pathways associated with vascular endothelial growth factor, platelet-derived growth factor and fibroblast growth factor signaling. By blocking these pathways, it helps reduce processes involved in abnormal angiogenesis and fibroblast activity, thereby slowing the progression of pulmonary fibrosis and certain cancers.

🔹 Key Benefits
Helps slow the decline of lung function in appropriate patients with progressive fibrotic lung disease.
Provides antifibrotic activity in idiopathic pulmonary fibrosis.
May be used for selected systemic-sclerosis-associated interstitial lung disease according to approved indications.
Has anticancer activity in specific NSCLC treatment regimens.
Available as an oral soft gelatin capsule for convenient administration.

🔹 Dosage And Administration
Nintib 150 mg should be taken only according to the prescription of a pulmonologist or oncologist. For adults with IPF, the commonly recommended regimen is 150 mg twice daily, approximately 12 hours apart, although dose adjustments may be required depending on tolerability and individual clinical factors.

The capsule should be taken with food, swallowed whole with water, and should not be chewed, crushed or opened. Treatment duration and dose adjustments should be determined by the treating physician.

🔹 Possible Side Effects
Possible side effects include:
Diarrhea
Nausea or vomiting
Abdominal pain
Reduced appetite
Weight loss
Headache
Increased liver enzymes
Fatigue
Gastrointestinal discomfort

More serious reactions can include significant liver injury, bleeding, gastrointestinal perforation and cardiovascular or thromboembolic events. Persistent or severe diarrhea and signs of liver problems require prompt medical attention.

🔹 Precautions And Warnings
Prescription-only medicine: Use under specialist supervision.
Liver-function tests should be performed before and during treatment as clinically indicated.
Patients with liver disease may require a different dose or may not be suitable for treatment.
Severe or persistent diarrhea should be reported to the treating physician.
Inform the doctor about bleeding disorders, cardiovascular disease, previous blood clots or gastrointestinal problems.
Nintedanib may increase bleeding risk, particularly when used with anticoagulant or antiplatelet medicines.
Women who may become pregnant should use appropriate contraception during treatment as advised by their healthcare professional.
Tell the doctor about all prescription medicines, supplements and herbal products being used.
Do not discontinue or modify treatment without medical advice.

🔹 Storage
Store Nintib 150 mg Soft Gelatin Capsules below 30°C, in the original packaging and protected from excessive heat, moisture and direct light. Keep out of reach of children.